Survival Outcomes and Prognostic Factors of Dermatofibrosarcoma Protuberans: A Population-Based Retrospective Cohort Analysis.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
31
8
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Limited information is available regarding survival outcomes and risk factors of dermatofibrosarcoma protuberans (DFSP). To investigate the clinicopathologic characteristics and survival outcomes of DFSP. The study cohort (7,567 patients) was selected from the Surveillance, Epidemiology, and End Results Program (2000-2018). Demographic and clinicopathologic variables, survival outcomes, and prognostic factors were analyzed. A total of 5,640 (74.53%) and 1,927 (25.47%) tumors were located in the skin and soft tissue, respectively. The median follow-up duration was 92 months. Median follow-up times were similar between patients with lymph node (107 months) and distant (102 months) metastases; the median survival time of the 89 patients (1.18%) who died of DFSP was significantly short (41 months, p < .001). Independent risk factors for cancer-specific mortality included age at diagnosis, histologic grade, and tumor size. Patients with tumors ≥10 cm in size or histologic grade III had significantly higher DFSP-specific mortality (7.07% and 10.08%, respectively, p < .001). Tumor locations and surgical procedures did not significantly influence survival. Dermatofibrosarcoma protuberans has a favorable survival prognosis, even in patients with node-positive or distant metastases. Dermatofibrosarcoma protuberans-specific mortality is significantly higher in patients with grade III or large (≥10 cm) tumors.
Sections du résumé
BACKGROUND
Limited information is available regarding survival outcomes and risk factors of dermatofibrosarcoma protuberans (DFSP).
OBJECTIVE
To investigate the clinicopathologic characteristics and survival outcomes of DFSP.
MATERIALS AND METHODS
The study cohort (7,567 patients) was selected from the Surveillance, Epidemiology, and End Results Program (2000-2018). Demographic and clinicopathologic variables, survival outcomes, and prognostic factors were analyzed.
RESULTS
A total of 5,640 (74.53%) and 1,927 (25.47%) tumors were located in the skin and soft tissue, respectively. The median follow-up duration was 92 months. Median follow-up times were similar between patients with lymph node (107 months) and distant (102 months) metastases; the median survival time of the 89 patients (1.18%) who died of DFSP was significantly short (41 months, p < .001). Independent risk factors for cancer-specific mortality included age at diagnosis, histologic grade, and tumor size. Patients with tumors ≥10 cm in size or histologic grade III had significantly higher DFSP-specific mortality (7.07% and 10.08%, respectively, p < .001). Tumor locations and surgical procedures did not significantly influence survival.
CONCLUSION
Dermatofibrosarcoma protuberans has a favorable survival prognosis, even in patients with node-positive or distant metastases. Dermatofibrosarcoma protuberans-specific mortality is significantly higher in patients with grade III or large (≥10 cm) tumors.
Identifiants
pubmed: 37384896
doi: 10.1097/DSS.0000000000003853
pii: 00042728-990000000-00429
pmc: PMC10461715
doi:
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
825-831Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society for Dermatologic Surgery, Inc.
Références
Dermatol Surg. 2016 Jan;42 Suppl 1:S24-31
pubmed: 26730971
J Clin Oncol. 2005 Oct 20;23(30):7669-75
pubmed: 16234529
J Am Acad Dermatol. 2022 Jun;86(6):1429-1431
pubmed: 34214620
Actas Dermosifiliogr (Engl Ed). 2018 Dec;109(10):868-877
pubmed: 30539729
J Eur Acad Dermatol Venereol. 2011 Dec;25(12):1385-91
pubmed: 21645124
Arch Dermatol. 2012 Sep;148(9):1055-63
pubmed: 22986859
Cancers (Basel). 2021 May 06;13(9):
pubmed: 34066400
J Orthop Traumatol. 2016 Sep;17(3):261-6
pubmed: 27289468
JAMA Dermatol. 2016 Dec 1;152(12):1365-1371
pubmed: 27262160
AJR Am J Roentgenol. 1994 Aug;163(2):391-4
pubmed: 8037038
Eur J Surg Oncol. 2017 Jun;43(6):1134-1141
pubmed: 28365129
Br J Dermatol. 2021 Apr;184(4):731-739
pubmed: 32599647
Ann Surg Oncol. 2015 Jan;22(1):248-55
pubmed: 25001093
J Am Acad Dermatol. 2014 Oct;71(4):781-6
pubmed: 24755121
Am J Surg Pathol. 1988 Apr;12(4):287-93
pubmed: 3354755
CA Cancer J Clin. 1992 Mar-Apr;42(2):116-25
pubmed: 1540852
Dermatol Surg. 2013 Oct;39(10):1417-33
pubmed: 24090253
Am J Dermatopathol. 2008 Aug;30(4):327-32
pubmed: 18645303
Ann Surg Oncol. 2011 Feb;18(2):328-36
pubmed: 20844969